Hormone therapies, primarily tamoxifen and aromatase inhibitors, have significantly improved prognosis and survival rates in HR+ breast cancers, yet 30% of patients have primary resistance to the therapy, due to acquired ESR1 mutations, and 40% of them eventually face high-risk situations for relapse 4,5. This evidence concerns the gene ESR1 and breast cancer.